<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Kylin Therapeutics</title>
	<atom:link href="http://www.kylintherapeutics.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.kylintherapeutics.com</link>
	<description>RNAi Interference</description>
	<lastBuildDate>Thu, 01 Jul 2010 14:35:17 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
		<item>
		<title>RNA Therapeutics Expert Joins Kylin&#8217;s Scientific Advisory Board</title>
		<link>http://www.kylintherapeutics.com/rna-therapeutics-expert-joins-kylins-scientific-advisory-board/</link>
		<comments>http://www.kylintherapeutics.com/rna-therapeutics-expert-joins-kylins-scientific-advisory-board/#comments</comments>
		<pubDate>Wed, 30 Jun 2010 14:21:57 +0000</pubDate>
		<dc:creator>edavis</dc:creator>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/?p=370</guid>
		<description><![CDATA[Officials at Kylin Therapeutics, Inc. announced Wednesday (June 30) that RNA interference and genetics expert John J. Rossi, Ph.D., will serve on the company&#8217;s Scientific Advisory Board. &#8220;John Rossi brings more than 30 years of research and experience in RNA interference (RNAi), molecular biology, genetics and gene therapy to our team,&#8221; said Eric Davis, president [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/rna-therapeutics-expert-joins-kylins-scientific-advisory-board/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Engineering RNA for Targeted siRNA Delivery and Medical Application.</title>
		<link>http://www.kylintherapeutics.com/engineering-rna-for-targeted-sirna-delivery-and-medical-application/</link>
		<comments>http://www.kylintherapeutics.com/engineering-rna-for-targeted-sirna-delivery-and-medical-application/#comments</comments>
		<pubDate>Wed, 09 Jun 2010 18:33:04 +0000</pubDate>
		<dc:creator>edavis</dc:creator>
				<category><![CDATA[Featured News]]></category>
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/?p=339</guid>
		<description><![CDATA[Department of Biomedical Engineering College of Engineering/College of Medicine, University of Cincinnati, Cincinnati, OH 45221, USA. RNA engineering for nanotechnology and medical applications is an exciting emerging research field. RNA has intrinsically defined features on the nanometre scale and is a particularly interesting candidate for such applications due to its amazing diversity, flexibility and versatility [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/engineering-rna-for-targeted-sirna-delivery-and-medical-application/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kylin Therapeutics brings Dr. Henry Li on as Director of Research and Development</title>
		<link>http://www.kylintherapeutics.com/kylin-therapeutics-brings-dr-henry-li-on-as-director-of-research-and-development/</link>
		<comments>http://www.kylintherapeutics.com/kylin-therapeutics-brings-dr-henry-li-on-as-director-of-research-and-development/#comments</comments>
		<pubDate>Thu, 06 May 2010 17:41:21 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=313</guid>
		<description><![CDATA[West Lafayette, IN – Kylin Therapeutics, Inc announced today its newest member to the research and development team, Dr. Henry Li. Dr. Li brings more than 13 years experience of biopharmaceutical R&#38;D, as well as additional years of academic research. Dr. Li began his career working at Immusol/iTherx Pharmaceuticals, a San Diego based biotechnology company, [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/kylin-therapeutics-brings-dr-henry-li-on-as-director-of-research-and-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kylin Therapeutics announces new patent surrounding pRNAi technology</title>
		<link>http://www.kylintherapeutics.com/kylin-therapeutics-announces-new-patent-surrounding-prnai-technology/</link>
		<comments>http://www.kylintherapeutics.com/kylin-therapeutics-announces-new-patent-surrounding-prnai-technology/#comments</comments>
		<pubDate>Tue, 06 Apr 2010 04:01:29 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=309</guid>
		<description><![CDATA[WEST LAFAYETTE, Ind. – Officials of Kylin Therapeutics, Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office (USPTO). &#8220;This patent represents new ground recognized in the field of RNA interference,&#8221; said Eric Davis, president and CEO of Kylin Therapeutics. &#8220;pRNAi is the only [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/kylin-therapeutics-announces-new-patent-surrounding-prnai-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kylin Therapeutics Receives Notice Of Allowance For Key Therapeutic RNA Patent Covering pRNAi Technology</title>
		<link>http://www.kylintherapeutics.com/test-number-3/</link>
		<comments>http://www.kylintherapeutics.com/test-number-3/#comments</comments>
		<pubDate>Wed, 07 Oct 2009 00:40:33 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=67</guid>
		<description><![CDATA[WEST LAFAYETTE, Ind. &#8211; Officials of Kylin Therapeutics Inc., a leading RNAi company, announced Tuesday (Oct. 6, 2009) that they have received a notice of allowance from U.S. Patent and Trademark Office for its first U.S. patent application.This newly allowed patent, exclusively licensed to Kylin by the Purdue Research Foundation, broadly covers a number of [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/test-number-3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>3 in Purdue Park named Companies to Watch</title>
		<link>http://www.kylintherapeutics.com/3-in-purdue-park-named-companies-to-watch/</link>
		<comments>http://www.kylintherapeutics.com/3-in-purdue-park-named-companies-to-watch/#comments</comments>
		<pubDate>Fri, 17 Jul 2009 18:00:31 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=228</guid>
		<description><![CDATA[WEST LAFAYETTE, Ind. &#8211; En&#8217;Urga, Kylin Therapeutics and Passageways, three Purdue Research Park-based firms, were named by the Indiana Economic Development Corp. in its second annual list of 50 Companies to Watch. &#8220;These three companies represent some of the key economic sectors &#8211; life sciences, information technology and engineering &#8211; that will diversify and strengthen [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/3-in-purdue-park-named-companies-to-watch/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kylin Therapeutics to expand cancer research with NIH funding</title>
		<link>http://www.kylintherapeutics.com/kylin-therapeutics-to-expand-cancer-research-with-nih-funding/</link>
		<comments>http://www.kylintherapeutics.com/kylin-therapeutics-to-expand-cancer-research-with-nih-funding/#comments</comments>
		<pubDate>Thu, 16 Jul 2009 18:03:31 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=230</guid>
		<description><![CDATA[WEST LAFAYETTE, Ind. &#8211; Kylin Therapeutics Inc. will expand its research into treating diseases including cancer and AIDS after receiving a $100,000 Phase I Small Business Innovation Research grant from the National Institutes of Health. The company&#8217;s technology is based on a Purdue University discovery called pRNA that utilizes a natural process, known as RNA [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/kylin-therapeutics-to-expand-cancer-research-with-nih-funding/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Grant to fuel development of disease-fighting technology</title>
		<link>http://www.kylintherapeutics.com/grant-to-fuel-development-of-disease-fighting-technology/</link>
		<comments>http://www.kylintherapeutics.com/grant-to-fuel-development-of-disease-fighting-technology/#comments</comments>
		<pubDate>Thu, 08 Jan 2009 18:05:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=232</guid>
		<description><![CDATA[Kylin Therapeutics announced Thursday (January 8th) its plans to further develop a Purdue University technology that could allow physicians to target drug delivery for treatment of diseases ranging from AIDS to cancer. The life sciences firm received a $1.2 million grant from the state’s 21st Century Research and Technology Fund to further bring its cancer [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/grant-to-fuel-development-of-disease-fighting-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indiana Biotech, Kylin Therapeutics, receives investment from Heartland Angels</title>
		<link>http://www.kylintherapeutics.com/indiana-biotech-kylin-therapeutics-receives-investment-from-heartland-angels/</link>
		<comments>http://www.kylintherapeutics.com/indiana-biotech-kylin-therapeutics-receives-investment-from-heartland-angels/#comments</comments>
		<pubDate>Mon, 10 Nov 2008 18:09:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=238</guid>
		<description><![CDATA[WEST LAFAYETTE, Ind. &#8211; Kylin Therapeutics Inc., a developer of next-generation RNAi therapeutics, announced that Heartland Angels of Skokie, Ill., has participated in Kylin’s Series A-1 offering. Heartland joins Golden Pine Ventures of Durham, N.C., in this round of financing. “The environment for biotech start-ups in Indiana is excellent, and investors from outside the state [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/indiana-biotech-kylin-therapeutics-receives-investment-from-heartland-angels/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Kylin Therapeutics to expand research efforts for its next-generation RNAi platform</title>
		<link>http://www.kylintherapeutics.com/kylin-therapeutics-to-expand-research-efforts-for-its-next-generation-rnai-platform/</link>
		<comments>http://www.kylintherapeutics.com/kylin-therapeutics-to-expand-research-efforts-for-its-next-generation-rnai-platform/#comments</comments>
		<pubDate>Thu, 02 Oct 2008 18:11:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.kylintherapeutics.com/Sandbox/KylinTherapeutics/?p=241</guid>
		<description><![CDATA[WEST LAFAYETTE, Ind. &#8211; Kylin Therapeutics, Inc., a developer of next-generation RNAi therapeutics, announced the expansion of its research and development efforts. The project will advance promising new RNAi cancer therapies. This expanded effort will be conducted at Purdue University’s Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing [...]]]></description>
		<wfw:commentRss>http://www.kylintherapeutics.com/kylin-therapeutics-to-expand-research-efforts-for-its-next-generation-rnai-platform/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
